Leveraging patents, trade secrets, or portions of an IP portfolio can often generate revenue streams, open new markets, or shut down competitors. We have advised small entrepreneurs and Fortune 500 corporations in virtually every type of IP-related transaction. We have helped clients set up and run licensing programs that have generated significant revenue streams, and we have worked with clients to pool patents and deal with standards issues. Our legal and technical experience and our background in the business of exploiting technology and IP assets bring our clients a strategic advantage. IP transactions, often global in nature, require a business-savvy partner with legal insight and technical expertise.
Transactions may be simple licenses for income or complex strategic alliances providing product and market access to both parties. We can analyze the potential for generating royalty income from existing IP rights, then formulate and execute licensing programs to help you realize full revenue potential. We advise on everything in a transaction program ranging from the initial confidential evaluation agreement through management of the portfolio of executed IP agreements. As business relationships evolve, we assist in enforcing or amending obligations in those agreements.
Finnegan is a pioneer in the development of IP licensing. Our lawyers have played an instrumental role in the establishment and ongoing management of the Licensing Executives Society (LES), and continue to serve in leadership roles in LES (USA and Canada) and LESI (International). We are recognized authorities in IP transactions law and serve as adjunct professors and contributing authors to licensing and transactional publications.
Finnegan is lead and preferred IP transactions counsel for one of the largest pharmaceutical companies in the world, handling more than 50 diligence projects each year, including all IP and related transactional aspects of the matters. The transactions span the full gamut of technologies from small molecule through biologics such as antibodies, oligonucleotides, and gene therapies. Finnegan also provides extensive assistance with post-deal integration procedures and subsequent global prosecution and portfolio strategy, ensuring a seamless transition of IP assets to the company and maximum value from acquired IP.
Developed internal framework governing manufacturer’s integration of artificial intelligence (AI) into software development workflows.
Drafted and negotiated settlement agreements, co-existence agreements, and licensing contracts across Latin American jurisdictions.
Negotiated global distribution and license agreement for film producer.
Analyzed music licensing agreements to advise music app developer and global hospitality company on rights, restrictions, and usage terms.
Lead open-source software audits for manufacturers to assess license compliance and usage risks.
Webinar
Top Ten Mistakes to Avoid in Negotiating and Drafting License and Collaboration Agreements
May 6, 2026
Webinar
European IP Blog
Munich Regional Court I Grants Avago Injunction Against Renault After Calculating a FRAND Rate
4 March 2026
Federal Circuit IP Blog
$85 million Verdict Affirmed: Federal Circuit Shuts Down Ingevity’s Challenge to Antitrust Verdict
February 27, 2026
Award/Ranking
Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked
May 28, 2026
Announcement
Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International
May 4, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.